Targeting TGFβ and therapies directed toward PD-1/PD-L1 or CTLA-4 amplifies tumor control by enabling a robust T cell response with improved CD4+ and CD8+ T cell activation and CD8+ T cell cytokine and cell killing capacity (113–116). This evidence concerns the gene CD274 and neoplasm.